Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TNXP, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Cyclobenzaprine FDA approved Aug 2025 · Tonmya |
Primary Fibromyalgia | Phase 3 · NCT02589275 | Completed |
| TNX-102 SL | Fibromyalgia | Phase 3 · NCT05273749 | Completed |
| Isometheptene Mucate | Tension-Type Headache | Phase 2 · NCT02423408 | Completed |
| TNX-1300 | Cocaine Intoxication | Phase 2 · NCT04996056 | Withdrawn |
| Cocaine Esterase | Cocaine Use | Phase 2 · NCT06045793 | Terminated |
| TNX-1500 | Kidney Transplant | Phase 2 · NCT07204080 | Not yet recruiting |
| TNX-1900 | Chronic Migraine | Phase 2 · NCT05679908 | Completed |
| Oxytocin | Pain | Phase 2 · NCT07730294 | Recruiting |
| Tianeptine | Depression | Phase 2 · NCT05686408 | Completed |
| TNX-201 | Healthy | Phase 1 · NCT02290379 | Completed |
| TNX-2110 | Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in… | Phase 1 · NCT05216510 | Terminated |
| TNX-102-C SL Tablets at 2.8 mg | Healthy Adults | Phase 1 · NCT01889173 | Completed |
| TNX-2120 | Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in… | Phase 1 · NCT05216510 | Terminated |
| TNX-2130 | Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in… | Phase 1 · NCT05216510 | Terminated |
| TNX-102-B SL Tablets at 2.8 mg | Healthy Adults | Phase 1 · NCT01889173 | Completed |
| Intranasal Oxytocin (IN-OXT) 24 IU single dose | Vasopressin Deficiency | Phase 1 · NCT04789148 | Recruiting |
Also used in these trials (approved or third-party drugs, not TNXP's own candidates): Cyclobenzaprine Hcl, Treprostinil.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TNXP holds $162.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $41.7M/quarter from operations, an estimated runway of 11.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 90 · High
These factors raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TNXP files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 5%+ holder (13G) | 1,100,964 | 5.67% | 2026-03-31 |
| Millennium Management LLC | 5%+ holder (13G) | 890,366 | 4.58% | 2026-06-09 |
| BlackRock, Inc. | Institution (13G, 5%+) | 854,579 | 4.40% | 2025-12-31 |
| Seth Lederman Chief Executive Officer, Director · +269,007 options |
Insider | 36,007 | 0.19% | 2026-11-11 |
| Richard Newcomb Stillwell Director · +32,700 options |
Insider | 5,000 | 0.03% | 2026-06-08 |
| Bradley Saenger Chief Financial Officer · +129,607 options |
Insider | 2,154 | 0.01% | 2026-06-30 |
| Carolyn E. Taylor Director · +32,700 options |
Insider | 1,833 | 0.01% | 2026-06-12 |
| Richard H Bagger Director · +32,700 options |
Insider | 1,000 | 0.01% | 2026-08-20 |
| Thomas Englese Chief Commercial Officer |
Insider | 694 | 0.00% | 2026-09-04 |
| James Treco Director · +32,700 options |
Insider | 250 | 0.00% | 2025-08-20 |
Share count 19,431,516 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-08-15 | Tonmya™ | NDA | +32.2% | -13.8% | -39.8% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TNXP and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →